First Vascular Access Company to Guarantee Hospitals Will See Cost Savings and Improved Overall Patient Outcomes

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

Today Access Scientific, LLC, manufacturer of POWERWAND™ midline and extended dwell catheters, reports they are now providing hospitals a guarantee that they will be able to reduce their central-line associated bloodstream infections (CLABSIs). The company also guarantees that hospitals will be able to reduce their use of one of the primary contributors to CLABSI — peripherally inserted central catheters (PICCs) — by a mimimum of 25%.

The guarantee aligns with the national initiative to reduce hospital acquired conditions (HACs) and stop putting patients through unnecessary risk. In the U.S., approximately 48 percent of ICU patients have indwelling central venous catheters, accounting for 15 million central line days per year1. Assuming an average CLABSI rate of 5.3 per 1000 catheter-days, as many as 79,500 CLABSIs are experienced each year in ICUs1.

CLABSI are an acute problem within healthcare, and Access Scientific guarantees it can help make a difference. At an average cost of $48,108 per infection2, this non-reimbursable HAC results in over $3 billion in related costs per year to the American healthcare system. Even more troubling, because CLABSIs have the highest mortality rate of any HAC at 18%1, as many as 14,000 U.S. patients die annually from CLABSI.

POWERWAND post-market surveillance demonstrates a reduction of CLABSIs by at least 10% when implemented as a part of an evidence-based, vascular-access-device patient program. Expanding these results nationally, the financial and clinical impact would be momentous, resulting in over 1,400 lives saved and $382.5 million in annual cost savings.

or patient stays longer than three days, the POWERWAND catheter is supported by overwhelming clinical evidence demonstrating a high completion of IV therapy. This performance allows hospitals to confidently utilize the POWERWAND as a solution for patients who previously would have been subjected to receiving a PICC.

When implementing an evidence-based VAD patient algorithm, hospitals have shown the ability to substantially reduce their PICC usage with the POWERWAND. This reduction in the overall use of central catheters has a direct impact on the total number of CLABSIs. Tables 1 and 2 demonstrate the proven outcomes associated with the POWERWAND through fewer CLABSIs and reduced overall PICC usage.

Table 1. PICC Reduction

Lead Author

Institution(s)

Scientific Journal

PICC Reduction

Moureau

Hospital 1 – Level-1 trauma center, 400-bed Magnet recognized teaching hospital

JAVA, 2015

58%

Pathak

Richmond University Medical Center

Infectious Diseases in Clinical Practice, 2015

37%

Hochman

NYU Langone

Vizient National Conference, 2018

69%

DeVries

Methodist Hospitals

AJIC, 2019

35%

Table 2. CLABSI Reduction

Lead Author

Institution

Scientific Journal

CLABSI Reduction

Moureau

Hospital 1 – Level-1 trauma center

Hospital 2 – 215 bed not-for-profit hospital

JAVA, 2015

Hospital 1 – 88%

Hospital 2 – 100%

Pathak

Richmond University Medical Center

Infectious Diseases in Clinical Practice, 2015

100%

Hochman

NYU Langone

Vizient National Conference, 2018

100%

DeVries

Methodist Hospitals

AJIC, 2019

Estimated 10 CLABSIs avoided

The above outcomes result in significant savings both in purchasing ($90 per POWERWAND vs cost of a PICC3) and clinical costs ($48,108 per CLABSI1).

As further incentive to healthcare providers, Access Scientific will provide meaningful compensation in the event a hospital fails to reach their targets.

This unique guarantee is based on the superior performance of the POWERWAND. Unlike other devices in its class, the POWERWAND is supported by nine peer reviewed publications and nine scientific posters. These post-market studies have documented reduced overall CLABSIs and significant cost savings when using the POWERWAND, a device that has recorded over 36,000 catheter-days with zero bloodstream infections. These results are the backbone of the risk share guarantee. They also underpin Access Scientific’s confidence to be a valuable partner for healthcare providers that are looking to improve overall patient outcomes and reduce costs. The risk share guarantee was designed to support value based decisions and truly make a difference.

spot_img

DON'T MISS

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.